PAX5 alterations in an infant case of KMT2A-rearranged leukemia with lineage switch

被引:3
|
作者
Nakajima, Koji [1 ]
Kubota, Hirohito [1 ]
Kato, Itaru [1 ]
Isobe, Kiyotaka [1 ]
Ueno, Hiroo [1 ]
Kozuki, Kagehiro [1 ]
Tanaka, Kuniaki [1 ]
Kawabata, Naoko [1 ]
Mikami, Takashi [1 ]
Tamefusa, Kosuke [2 ]
Nishiuchi, Ritsuo [2 ]
Saida, Satoshi [1 ]
Umeda, Katsutsugu [1 ]
Hiramatsu, Hidefumi [1 ]
Adachi, Souichi [3 ]
Takita, Junko [1 ]
机构
[1] Kyoto Univ, Grad Sch Med, Dept Pediat, Kyoto, Japan
[2] Kochi Hlth Sci Ctr, Dept Pediat, Kochi, Japan
[3] Kyoto Univ, Grad Sch Med, Dept Human Hlth Sci, Kyoto, Japan
关键词
infant leukemia; KMT2A rearrangement; lineage switch; PAX5; whole exome sequencing; CELL;
D O I
10.1111/cas.15380
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Lineage switch is a rare event at leukemic relapse. While mostly known to occur in KMT2A-rearranged infant leukemia, the underlying mechanism is yet to be depicted. This case report describes a female infant who achieved remission of KMT2A-MLLT3-rearranged acute monocytic leukemia, but 6 months thereafter, relapsed as KMT2A-MLLT3-rearranged acute lymphocytic leukemia. Whole exome sequencing of the bone marrow obtained pre-post lineage switch revealed two somatic mutations of PAX5 in the relapse sample. These two PAX5 alterations were suggested to be loss of function, thus to have played the driver role in the lineage switch from acute monocytic leukemia to acute lymphocytic leukemia.
引用
收藏
页码:2472 / 2476
页数:5
相关论文
共 50 条
  • [21] Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy
    Cheung, Laurence C.
    Aya-Bonilla, Carlos
    Cruickshank, Mark N.
    Chiu, Sung K.
    Kuek, Vincent
    Anderson, Denise
    Chua, Grace-Alyssa
    Singh, Sajla
    Oommen, Joyce
    Ferrari, Emanuela
    Hughes, Anastasia M.
    Ford, Jette
    Kunold, Elena
    Hesselman, Maria C.
    Post, Frederik
    Faulk, Kelly E.
    Breese, Erin H.
    Guest, Erin M.
    Brown, Patrick A.
    Loh, Mignon L.
    Lock, Richard B.
    Kees, Ursula R.
    Jafari, Rozbeh
    Malinge, Sebastien
    Kotecha, Rishi S.
    LEUKEMIA, 2023, 37 (01) : 61 - 71
  • [22] Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy
    Laurence C. Cheung
    Carlos Aya-Bonilla
    Mark N. Cruickshank
    Sung K. Chiu
    Vincent Kuek
    Denise Anderson
    Grace-Alyssa Chua
    Sajla Singh
    Joyce Oommen
    Emanuela Ferrari
    Anastasia M. Hughes
    Jette Ford
    Elena Kunold
    Maria C. Hesselman
    Frederik Post
    Kelly E. Faulk
    Erin H. Breese
    Erin M. Guest
    Patrick A. Brown
    Mignon L. Loh
    Richard B. Lock
    Ursula R. Kees
    Rozbeh Jafari
    Sébastien Malinge
    Rishi S. Kotecha
    Leukemia, 2023, 37 : 61 - 71
  • [23] A distinct core regulatory module enforces oncogene expression in KMT2A-rearranged leukemia
    Harada, Taku
    Heshmati, Yaser
    Kalfon, Jeremie
    Perez, Monika W.
    Ferrucio, Juliana Xavier
    Ewers, Jazmin
    Engler, Benjamin Hubbell
    Kossenkov, Andrew
    Ellegast, Jana M.
    Yi, Joanna S.
    Bowker, Allyson
    Zhu, Qian
    Eagle, Kenneth
    Liu, Tianxin
    Kai, Yan
    Dempster, Joshua M.
    Kugener, Guillaume
    Wickramasinghe, Jayamanna
    Herbert, Zachary T.
    Li, Charles H.
    Koren, Jost Vrabic
    Weinstock, David M.
    Paralkar, Vikram R.
    Nabet, Behnam
    Lin, Charles Y.
    Dharia, Neekesh, V
    Stegmaier, Kimberly
    Orkin, Stuart H.
    Pimkin, Maxim
    GENES & DEVELOPMENT, 2022, 36 (5-6) : 368 - 389
  • [24] UTX loss alters therapeutic responses in KMT2A-rearranged acute myeloid leukemia
    Xinyue Zhou
    Pengcheng Zhang
    Sajesan Aryal
    Lixia Zhang
    Rui Lu
    Leukemia, 2023, 37 : 226 - 230
  • [25] To B or Not to B: Utility of PAX5 in Lineage Assignment of Acute Leukemia
    Cedeno, Ernest Hidalgo
    Germans, Sharon Koorse
    Pan, Zenggang
    Weinberg, Olga
    Xu, Mina
    LABORATORY INVESTIGATION, 2024, 104 (03) : S1412 - S1413
  • [26] UTX loss alters therapeutic responses in KMT2A-rearranged acute myeloid leukemia
    Zhou, Xinyue
    Zhang, Pengcheng
    Aryal, Sajesan
    Zhang, Lixia
    Lu, Rui
    LEUKEMIA, 2023, 37 (01) : 226 - 230
  • [27] NOVEL COMPOUNDS SYNERGIZE WITH VENETOCLAX TO TARGET KMT2A-REARRANGED ACUTE MYELOID LEUKEMIA
    Tregnago, C.
    Benetton, M.
    Da Ros, A.
    Borella, G.
    Longo, G.
    Polato, K.
    Francescato, S.
    Biffi, A.
    Pigazzi, M.
    HAEMATOLOGICA, 2022, 107 : 67 - 68
  • [28] Extramedullary relapse of KMT2A(MLL)-rearranged acute lymphoblastic leukemia with lineage switch following blinatumomab
    Aldoss, Ibrahim
    Song, Joo Y.
    BLOOD, 2018, 131 (22) : 2507 - 2507
  • [29] Identification of Novel Cell Surface Therapeutic Targets for KMT2A-Rearranged Acute Myeloid Leukemia
    Theret, Louis
    Bordeleau, Marie-Eve
    Hajmirza, Azadeh
    Metois, Arnaud
    Moujaber, Ossama
    Audemard, Eric
    Spinella, Jean-Francois
    Chagraoui, Jalila
    Aubert, Leo
    Farah, Azer
    Lisi, Veronique
    Bonneil, Eric
    Boivin, Isabel
    Mayotte, Nadine
    MacRae, Tara
    Thibault, Pierre
    Lemieux, Sebastien
    Lavallee, Vincent-Philippe
    Hebert, Josee
    Sauvageau, Guy
    Roux, Philippe P.
    BLOOD, 2022, 140 : 6316 - 6317
  • [30] DYRK1A Is Regulated By Oncogenic KMT2A and Required for Survival of KMT2A-Rearranged Acute Lymphoblastic Leukemia
    Hurtz, Christian
    Wertheim, Gerald
    Bhansali, Rahul S.
    Lehman, Anne
    Jeschke, Grace
    Crispino, John D.
    Besson, Thierry
    Tasian, Sarah K.
    Carroll, Martin
    BLOOD, 2019, 134